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Abstract
Objectives—Using published, nationally-representative estimates, we calculated the total 
number of perinatally HIV-exposed and HIV-infected infants born during 1978–2010, the number 
of perinatal HIV cases prevented by interventions designed for the prevention of mother-to-child 
transmission (PMTCT), and the number of infants exposed to antiretroviral (ARV) drugs during 
the prenatal and intrapartum periods.
Design—We calculated the number of infants exposed to ARV drugs since 1994, and the number 
of cases of mother-to-child HIV transmission prevented from 1994 to 2010 using published data. 
We generated confidence limits for our estimates by performing a simulation study.
Methods—Data were obtained from published, nationally-representative estimates from the 
Centers for Disease Control and Prevention. Model parameters included the annual numbers of 
HIV-infected pregnant women, the annual numbers of perinatally infected infants, the annual 
proportions of infants exposed to ARV drugs during the prenatal and intrapartum period and the 
estimated MTCT rate in the absence of preventive interventions. For the simulation study, model 
parameters were assigned distributions and we performed 1,000,000 repetitions.
Results—Between 1978 and 2010, an estimated 186,157 [95% confidence interval (CI): 
185,312–187,003] HIV-exposed infants and approximately 21,003 (95% CI: 20,179–21,288) HIV-
infected infants were born in the United States. Between 1994 and 2010, an estimated 124,342 
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(95% CI: 123,651–125,034) HIV-exposed infants were born in the US, and approximately 6083 
(95% CI: 5931–6236) infants were perinatally infected with HIV. During this same period, about 
100,207 (95% CI: 99,374–101,028) infants were prenatally exposed to ARV drugs. As a result of 
PMTCT interventions, an estimated 21,956 (95% CI: 20,191–23,759) MTCT HIV cases have been 
prevented in the United States since 1994.
Conclusion—Although continued vigilance is needed to eliminate mother-to-child HIV 
transmission, PMTCT interventions have prevented nearly 22,000 cases of perinatal HIV 
transmission in the United States since 1994.
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The first cases of perinatally acquired human immunodeficiency virus 1 (HIV) in the United 
States probably occurred in 1978.1 In 1994, the United States Public Health Service Task 
Force (USPHS) recommended the use of zidovudine to reduce perinatal transmission of 
HIV,2 based on clinical trial results.3 In subsequent years, other interventions for prevention 
of mother-to-child transmission (PMTCT) were recommended, including use of combination 
antiretroviral (ARV) treatment in 1997,4 and elective cesarean section delivery for women 
with HIV viral loads greater than 1000 copies/mL.5 The recommendation of opt-out HIV 
testing for pregnant women was introduced in 19996 with the goal of increasing the 
proportion of women whose HIV status was known before delivery, allowing more HIV-
infected pregnant women to receive preventive interventions during pregnancy.7 Avoidance 
of breastfeeding by HIV-infected women has been recommended in high-resource settings 
since 19858; breastfeeding by HIV-infected women has been estimated to increase the risk of 
mother-to-child HIV transmission by an additional 14%.9 The Enhanced Perinatal 
Surveillance system of the US Centers for Disease Control and Prevention (CDC) estimated 
the rate of MTCT in the United States as 1.7%–2.9% during 2005–2008,10,11 although by 
2003 MTCT rates of less than 1% had been reported in a large European cohort.4
HIV case reporting to state surveillance systems has been conducted in some states since 
1985,12 although confidential name-based HIV infection reporting was not implemented in 
all US states and territories until 2008.13 At present, perinatal HIV exposure reporting is 
conducted in only a subset of these jurisdictions. It has, therefore, been difficult to determine 
the annual numbers of HIV-infected women delivering infants and of perinatally infected 
infants.7 Reports of perinatally acquired AIDS cases have been the only data that have been 
consistently available from all US jurisdictions over time, from the early years of the 
epidemic. However, using these data to estimate the incidence of perinatal HIV infection is 
challenging and requires indirect estimation through statistical methods.1,14,15 Nevertheless, 
there have been several national estimates of the annual numbers of HIV-infected 
infants1,15–19 and the annual numbers of infants born to HIV-infected women (HIV-exposed 
infants), as well as national estimates for the annual proportions of HIV-infected pregnant 
women prescribed ARVs during the prenatal and intrapartum periods.7,10,20,21 Neither the 
annual numbers of perinatal HIV cases prevented by PMTCT interventions nor the annual 
numbers of infants perinatally exposed to ARV have previously been estimated for the entire 
United States. The latter figure is significant because it reflects the population of infants and 
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children who may be at risk for toxicities from ARV use, prenatal ARV use in particular. 
Although several studies have indicated very low rates of birth defects or 
carcinogenicity,22–25 the possible increased risk of mitochondrial and other toxicities in 
infants and children who were perinatally exposed to ARV drugs26,27 warrants long-term 
follow-up of these infants.
The objectives of the present study were to use national estimates previously published by 
CDC to estimate the number of perinatally HIV-exposed and HIV-infected infants in the 
United States since the beginning of the HIV epidemic, the number of perinatal HIV 
infections prevented and the number of HIV-exposed infants perinatally exposed to ARVs in 
the United States during 1994–2010, a period of increasing ARV use.
MATERIALS AND METHODS
We identified data from several published sources (Table 1, columns 1b, 1f) for the annual 
numbers of HIV-infected pregnant women who delivered (column 1c) and the annual 
numbers of HIV-infected infants born (column 1g) for 1978–2010. When available, we used 
published point estimates or, if only ranges were given, the midpoints of those ranges, as the 
best estimates of these annual numbers. When data were not available, we linearly 
interpolated or extrapolated the available data to obtain estimated numbers for each year 
(columns 1d, 1h). For the years 2007–2010, data were not available on the numbers of births 
to HIV-infected women, so the 2006 estimate was carried forward to be conservative in our 
final estimate of the number of perinatal HIV infections averted. For 1978–1987, we 
estimated the annual numbers of HIV-infected women (column 1d) as 4.4346 times the 
annual numbers of HIV-infected infants estimated by Davis et al1 (column 1g), where 
4.4346 = 1/0.2255 is the reciprocal of the HIV MTCT transmission rate in the absence of 
ARV prophylaxis, estimated from the placebo arm of the completed AIDS clinical trials 
group (ACTG) 076 trial.3 Note that 1978 is the first year in which HIV-infected infants were 
born in the United States, according the AIDS-based back-calculation.1
In the absence of variance estimates, we assumed that the estimated annual numbers 
(columns 1d, 1h) represented count data and calculated exact 95% confidence intervals (CIs) 
using the Poisson distribution (columns 1e, 1i). We then estimated the annual numbers of 
HIV MTCT cases that would have occurred in the absence of ARVs as the product of the 
annual numbers of HIV-infected women (column 1d) times the HIV MTCT rate of 0.2255.3 
In turn, we estimated the annual numbers of perinatal HIV cases prevented (column 1j) after 
the introduction of ARV prophylaxis in 1994 as the differences between the annual numbers 
of HIV MTCT cases that would have occurred in the absence of ARVs and the annual 
numbers of HIV-infected infants born each year (column 1h).
We performed a simulation study with 1,000,000 repetitions to obtain 95% CIs for the 
annual numbers of perinatal HIV cases prevented (column 1k) for 1994–2010. All 
simulations were performed using SAS software, version 9.3 (SAS Institute, Inc, Cary, NC). 
First, for each repetition, we simulated the annual numbers of HIV-infected women from 
Poisson distributions with mean parameters equal to (column 1d). Second, we simulated the 
annual numbers of HIV-infected infants from Poisson distributions with mean parameters 
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equal to (column 1h). Third, we simulated the HIV MTCT rate as a β variable with 
parameters 46 and 158, corresponding to the number of transmissions and nontransmissions 
observed in the placebo arm of the ACTG 076 trial.3 Fourth, we simulated the annual 
numbers of HIV MTCT cases that would have occurred in the absence of ARVs as binomial 
variables with proportion parameters equal to the simulated HIV MTCT rate and sizes equal 
to the simulated numbers of HIV-infected women. Fifth, we computed the annual numbers 
of perinatal HIV cases since the 1994 USPHS recommendations to use zidovudine to reduce 
perinatal HIV transmission as the differences between the simulated annual numbers of HIV 
MTCT cases that would have occurred in the absence of ARVs and the simulated annual 
numbers of HIV-infected infants. Finally, we computed the 0.025 and the 0.975 percentiles 
over all 1,000,000 repetitions to obtain the bounds of the 95% CIs for the annual numbers of 
perinatal HIV cases prevented (column 1k).
We also identified data from several published sources (Table 2, column 2b) for the annual 
numbers of infants exposed to prenatal and intrapartum ARVs (columns 2c, 2i) among a 
sample of infants born to HIV-infected women (columns 2d, 2j) for 1994–2010. For 1994–
1998, we obtained the unpublished data used to create the figures in the source paper.28 We 
calculated the annual raw proportions of infants exposed to prenatal ARVs (column 2e) as 
(column 2c) divided by (column 2d) and the annual raw proportions of infants exposed to 
intrapartum ARVs (column 2k) as (column 2i) divided by (column 2j).
Next, we fit a logistic regression model29 to the annual numbers of infants exposed to 
prenatal ARVs (column 2c) among a sample of infants born to HIV-infected women (column 
2d) using year (column 2a) as a linear predictor. Similarly, we fit a logistic regression model 
to the annual numbers of infants exposed to intrapartum ARVs (column 2i) among a sample 
of infants born to HIV-infected women (column 2j) using year (column 2a) as a quadratic 
predictor (centered on 1990). We assumed that the true annual proportions of prenatal and 
intrapartum ARV usage were monotonically increasing over time. A separate term was fit 
for 1994, the first year ARVs were available, because the proportions for this year was so 
much lower than for the other years. We obtained smoothed proportions of infants exposed 
to prenatal and intrapartum ARVs (columns 2f, 2l). Fitting these logistic regression models 
allowed us to interpolate and extrapolate to years for which data were not available and gave 
tighter estimates of the true proportions for each year. In turn, we estimated the annual 
numbers of infants exposed to prenatal and intrapartum ARVs (columns 2g, 2m) as the 
product of the annual numbers of HIV-infected pregnant women who delivered (column 1d) 
and the annual smoothed proportions of infants exposed to prenatal and intrapartum ARVs 
(columns 2f, 2l), respectively.
We also used the above simulation study with 1,000,000 repetitions to obtain 95% CIs for 
the annual numbers of infants exposed to prenatal and intrapartum ARVs (columns 2h, 2n) 
for 1994–2010. First, for each repetition, we simulated the annual numbers of HIV-infected 
women from a Poisson distribution with mean parameter equal to (column 1d). Second, we 
simulated the annual proportions of infants exposed to prenatal and intrapartum ARVs from 
the logistic regression equations obtained above. Third, we simulated the annual numbers of 
infants exposed to prenatal and intrapartum ARVs as binomial variables with proportion 
parameters equal to the simulated proportions of infants exposed to prenatal and intrapartum 
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ARVs, respectively, and sizes equal to the simulated number of HIV-infected women. 
Finally, we computed the 0.025 and the 0.975 percentiles over all 1,000,000 repetitions to 
obtain the bounds of the 95% CIs for the annual numbers of infants exposed to prenatal and 
intrapartum ARVs (columns 2h, 2n).
RESULTS
Using the data sources listed in the Tables 1 and 2, we estimated that between 1978 and 
2010 approximately 186,157 (95% CI: 185,312–187,003) HIV-infected women gave birth in 
the United States (Table 1). The annual number of HIV-infected women giving birth 
increased approximately 28-fold during this period, from 310 in 1978 at the start of the 
epidemic to 8700 in 2006.30 During this period, approximately 21,003 (95% CI: 20,719–
21,288) infants were perinatally infected with HIV. The estimated annual number of 
perinatal HIV infections peaked in 1991 at 17601 and declined steadily after 1993 to 151 
(95% CI: 127–176) in 2010.16 The change in the estimated incidence of perinatal HIV 
infection during this period is depicted in Figure 1.
Focusing on the perinatal prophylaxis era between 1994 and 2010, an estimated 124,342 
(95% CI: 123,651–125,034) HIV-infected women gave birth in the United States (Table 1). 
The annual number of HIV-infected women delivering increased by approximately 42%, 
from 6145 in 1994 to 8700 in 2010. During this same period, the annual number of HIV-
infected infants decreased from 1263 (95% CI: 1194–1333) to approximately 151 (95% CI: 
127–176).16 The annual MTCT rate dropped from a high of 20.6% in 1994 to a low of 1.7% 
in 2010. In total, approximately 6083 (95% CI: 5931–6236) infants were infected with HIV 
perinatally during this period. As a result of PMTCT interventions, an estimated 21,956 
(95% CI: 20,191–23,759) cases of perinatal HIV were prevented between 1994 and 2010. In 
addition, after the introduction of ARVs, an increasing proportion of expected cases of 
MTCT were prevented each year; only about 9% of expected cases of MTCT were 
prevented in 1994, compared with 92% in 2010 (data not shown).
Both prenatal and intrapartum ARV use increased from 1994 to 2010 (Table 2). In 1994, 
approximately 54% of women received prenatal ARVs, resulting in 3293 (95% CI: 2794–
3784) infant ARV exposures. By 2010, the proportion of HIV-infected pregnant women 
receiving ARVs during the prenatal period had risen to 87%, and 7558 (95% CI: 7366–7749) 
infants were exposed to ARVs that year. Altogether, an estimated 100,207 (95% CI: 99,374–
101,028) infants were exposed to ARV drugs during the prenatal period.
The proportion of women receiving ARVs during the intrapartum period increased 
substantially during this period, from 32% in 1994 to 87% in 2010 (Table 2). The estimated 
annual number of infants exposed to ARVs during the intrapartum period grew from 1968 
(95% CI: 1537–2456) in 1994 to 7580 (95% CI: 7340–7810) in 2010. In total, an estimated 
97,182 (95% CI: 96,320–98,051) infants were exposed to intrapartum ARVs from 1994 to 
2010.
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PMTCT interventions—including HIV testing for pregnant women, ARV prophylaxis, 
avoidance of breastfeeding and elective cesarean section—have dramatically reduced the 
rates of MTCT of HIV in the United States. However, during the years of this study, a lack 
of national HIV infection and perinatal HIV exposure reporting has made it difficult to 
determine the full impact of these interventions. Strategies such as opt-out HIV testing for 
pregnant women, rapid testing at labor and delivery and improved ARV drugs have played 
significant roles in identifying HIV infections in pregnant women and preventing perinatal 
transmission. We estimate that nearly 22,000 perinatal HIV infections were prevented 
between 1994 and 2010 as a result of PMTCT interventions, suggesting that by 2010 the 
number of infants in whom HIV infection was prevented in the United States had exceeded 
the number of cases that have occurred. A growing share of perinatal HIV cases was 
prevented each year after the introduction of ARV prophylaxis.
We estimate that approximately 21,000 infants have been perinatally infected with HIV 
between 1978 and 2010. As of 2010, the CDC National HIV Surveillance System reported 
approximately 10,500 persons living with diagnoses of perinatally acquired HIV infection,13 
of whom 7959 were ≥13 years of age and 2541 were <13 years of age. The implication of 
these figures is that, overall, approximately half (10,500/21,003) of the perinatally infected 
persons born within the United States were living as of 2010; of those born before 1999 (ie, 
≥13 years old in 2011), approximately 43% (7959/18,402) were living, and of those born 
since 1998 (ie, < 13 years old in 2011), approximately 98% (2541/2601) were living.
An increasing proportion of infants born to HIV-infected women were exposed to ARV 
drugs during the prenatal or intrapartum periods. By 2010, more than 100,000 infants had 
been exposed to ARV prenatally. While widespread ARV prophylaxis has produced 
significant PMTCT successes, challenges remain. Although the number of HIV-infected 
pregnant women receiving prenatal ARV prophylaxis has increased annually, the proportion 
of women receiving ARVs during the prenatal period appears to have remained relatively 
stable since 2004, when an estimated 83% received prenatal ARVs.7 We estimated that 
approximately 87% of HIV-infected pregnant women received prenatal ARV prophylaxis in 
2010.
Other studies have highlighted the role of missed HIV prevention opportunities, including 
late or no maternal HIV testing, inadequate ARV prophylaxis, breastfeeding or low maternal 
CD4 cell counts.11 Addressing these missed prevention opportunities is crucial to the 
elimination of perinatal HIV transmission. Efforts to identify HIV infections and provide 
timely treatment for women before or early in pregnancy need continued support.
Whereas ARV drugs have played an important role in reducing the MTCT rate, recent 
research has also explored potential toxicities associated with fetal/infant ARV drug 
exposure, including low birth weight, congenital abnormalities, childhood cancers and 
mitochondrial dysfunction.23–25,27,31–36 While a number of observational studies have found 
an association between maternal combination ARV therapy (now simply known as ARV 
therapy) and infant prematurity,35,37–39 this relationship has not been consistently 
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observed.40–42 A recent meta-analysis (including studies from the United States), however, 
found that exposure to ARV therapy during pregnancy did not increase the odds of 
premature birth.36 Other adverse outcomes such as mitochondrial dysfunction are thought to 
be rare.43 Estimates of the number of individuals exposed to these drugs during the prenatal 
or intrapartum periods may help investigators plan future research on potential adverse 
effects of perinatal ARV drug exposure.
Preventing cases of MTCT directly through ARV prophylaxis affects the health of 
perinatally exposed infants by eliminating HIV-associated morbidity and mortality. 
Reducing rates of perinatal HIV transmission likely also leads to decreased healthcare 
utilization costs that are associated with HIV testing, treatment, in-patient care and 
outpatient care, and laboratory monitoring,44 and reductions in the levels of overall HIV-
associated health system spending.45,46 In addition to health system costs, perinatal HIV 
infections also have economic ramifications for individuals, families and society. Preventing 
perinatal HIV reduces annual expenditures on HIV care and treatment for people living with 
HIV, their families and the wider US healthcare system. Calculating the cost-effectiveness of 
perinatal HIV transmission prevention interventions may be an avenue for future research.
Limitations
This analysis was based on the best available nationally representative estimates. However, a 
lack of national, HIV infection (during the time of the study) and perinatal HIV exposure 
reporting made the annual numbers of HIV-infected pregnant women and infants difficult to 
determine with precision. Several of the published estimates by CDC involved modeling, 
including “back-calculations” from numbers of AIDS cases. The modeled data were limited 
to numbers of HIV-infected women delivering, and the numbers of HIV-exposed and HIV-
infected infants. This analysis was limited by missing data for several years during our 
period of interest. Our method of estimation assumed a constant rate of change for unknown 
years, when the actual rate of change may have been substantially more variable. Notably, 
we assumed no change in the annual number of HIV-infected women delivering after 2006, 
whereas that number might have increased in that period. The annual number of infected 
infants was last modeled for 2009, and we assumed that the number did not change in 2010. 
Estimates for the annual number of HIV-infected pregnant women and their infants who 
were exposed to ARV drugs are subject to the same limitations. For several years of ARV 
data, we had to use raw data, as opposed to that which was published. In the absence of 
consistent nationwide data on the number of HIV-infected infants, we relied on published 
numbers derived from models; for consistency’s sake, we used only CDC data.
CONCLUSION
This study provides the first national estimates of the number of HIV-infected pregnant 
women, HIV-infected infants and the number of perinatal HIV cases prevented by PMTCT 
interventions in the United States. Using these estimates, we calculated the number of 
prenatal and intrapartum ARV exposures among infants born to HIV-infected mothers. 
These estimates will be important for policy-making and provide reference data for future 
studies, including those on ARV toxicities and those on net-savings associated with PMTCT 
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programs. Great progress has been made in the prevention of MTCT of HIV since the 
introduction of ARVs and other preventive interventions; PMTCT interventions have 
prevented nearly 22,000 cases of MTCT of HIV between 1994 and 2010. However, 
continued vigilance to prevent, identify and treat HIV infections in women must be 
undertaken to eliminate perinatal HIV in the United States.
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Numbers of HIV-infected pregnant women, HIV-infected infants, and expected HIV-infected 
infants in the absence of ARVs, United States, 1978–2010. Since the USPHS 
recommendation in 1994 to use zidovudine to reduce perinatal HIV transmission, the annual 
number of HIV-infected women giving birth (closed circles, published data; open circles, 
interpolated or extrapolated data) continued to increase, from approximately 6145 women in 
1994, to an estimated 8700 in 2010. The dotted line indicates 0.2255 times the annual 
number of HIV-infected pregnant women, which estimates the annual number of HIV-
infected infants that would have occurred in the absence of ARV prophylaxis (open squares), 
introduced in 1994.2 The annual number of perinatally HIV-infected infants (closed 
triangles, published data; open triangles, interpolated or extrapolated data) declined by about 
88% after 1994, a decline due to increasing proportions of HIV-infected pregnant women 
who received ARV prophylaxis during the prenatal and intrapartum periods, in addition to 
other preventive interventions.
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